Literature DB >> 32434943

zzm321990 Chronic morphine-induced changes in signaling at the A3 adenosine receptor contribute to morphine-induced hyperalgesia, tolerance and withdrawal.zzm321990

Timothy M Doyle1, Tally Marie Largent-Milnes2, Zhoumou Chen3, Vicky Staikopoulos4, Emanuela Esposito5, Rebecca Delgarno6, Churmy Fan6, Dilip K Tosh7, Salvatore Cuzzocrea8, Kenneth A Jacobson9, Tuan Trang6, Mark R Hutchinson10, Gary J Bennett11, Todd W Vanderah12, Daniela Salvemini13.   

Abstract

Treating chronic pain using opioids, such as morphine, is hampered by the development of opioid-induced hyperalgesia (OIH; increased pain sensitivity), antinociceptive tolerance and withdrawal which can contribute to dependence and abuse. In the central nervous system, the purine nucleoside adenosine has been implicated in beneficial and detrimental actions of morphine, but the extent of their interaction remains poorly understood. Here, we demonstrate that morphine-induced OIH and antinociceptive tolerance in rats is associated with a 2-fold increase in adenosine kinase (ADK) expression in the dorsal horn of the spinal cord (DH-SC). Blocking ADK activity in the spinal cord provided greater than 90% attenuation of OIH and antinociceptive tolerance through A3 adenosine receptor (A3AR) signaling. Supplementing adenosine signaling with selective A3AR agonists blocked OIH and antinociceptive tolerance in rodents of both sexes. Engagement of A3AR in the spinal cord with an ADK inhibitor or A3AR agonist was associated with reduced DH-SC expression of the NOD-like receptor pyrin domain-containing 3 (NLRP3; 60-75%), cleaved caspase 1 (40-60%), interleukin (IL)-1β (76-80%) and tumor necrosis factor (TNF; 50-60%). In contrast, the neuroinhibitory and anti-inflammatory cytokine IL-10 increased 2-fold. In mice, A3AR agonists prevented the development of tolerance in a model of neuropathic pain and reduced naloxone-dependent withdrawal behaviors by greater than 50%. These findings suggest A3AR-dependent adenosine signaling is compromised during sustained morphine to allow the development of morphine-induced adverse effects. These findings raise the intriguing possibility that A3AR agonists may be useful adjunct to opioids to manage their unwanted effects.
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Keywords:  Adenosine; Adenosine receptors; Neuroinflammation; morphine; tolerance

Year:  2020        PMID: 32434943     DOI: 10.1124/jpet.120.000004

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Blocking of Caveolin-1 Attenuates Morphine-Induced Inflammation, Hyperalgesia, and Analgesic Tolerance via Inhibiting NLRP3 Inflammasome and ERK/c-JUN Pathway.

Authors:  Wenling Liu; Peng Jiang; Liuji Qiu
Journal:  J Mol Neurosci       Date:  2022-03-09       Impact factor: 3.444

2.  A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity.

Authors:  Dilip K Tosh; Veronica Salmaso; Ryan G Campbell; Harsha Rao; Amelia Bitant; Eline Pottie; Christophe P Stove; Naili Liu; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  Eur J Med Chem       Date:  2021-11-19       Impact factor: 6.514

3.  Role of Adenosine Kinase in Sphingosine-1-Phosphate Receptor 1-Induced Mechano-Hypersensitivities.

Authors:  Filomena Lauro; Luigino Antonio Giancotti; Grant Kolar; Caron Mitsue Harada; Taylor A Harmon; Timothy J Garrett; Daniela Salvemini
Journal:  Cell Mol Neurobiol       Date:  2021-11-13       Impact factor: 4.231

4.  Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10.

Authors:  Mariaconcetta Durante; Silvia Squillace; Filomena Lauro; Luigino Antonio Giancotti; Elisabetta Coppi; Federica Cherchi; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Grant Kolar; Carrie Wahlman; Adeleye Opejin; Cuiying Xiao; Marc L Reitman; Dilip K Tosh; Daniel Hawiger; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 5.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

6.  Adenosine Metabotropic Receptors in Chronic Pain Management.

Authors:  Livio Luongo; Francesca Guida; Sabatino Maione; Kenneth A Jacobson; Daniela Salvemini
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

7.  Purines in Pain as a Gliopathy.

Authors:  Giulia Magni; Stefania Ceruti
Journal:  Front Pharmacol       Date:  2021-03-10       Impact factor: 5.810

Review 8.  Adenosine receptors: Emerging non-opioids targets for pain medications.

Authors:  Soo-Min Jung; Lee Peyton; Hesham Essa; Doo-Sup Choi
Journal:  Neurobiol Pain       Date:  2022-03-25

9.  Spinal A3 adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats.

Authors:  Heather Leduc-Pessah; Cynthia Xu; Churmy Y Fan; Rebecca Dalgarno; Yuta Kohro; Sydney Sparanese; Nikita N Burke; Kenneth A Jacobson; Christophe Altier; Daniela Salvemini; Tuan Trang
Journal:  J Neurosci Res       Date:  2021-06-01       Impact factor: 4.433

Review 10.  Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.

Authors:  Fabrizio Vincenzi; Silvia Pasquini; Pier Andrea Borea; Katia Varani
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.